.png)
Staff Profile
Professor Deborah Tweddle
Professor of Paediatric Oncology
- Email: deborah.tweddle@ncl.ac.uk
- Telephone: +44 (0) 191 208 2230
- Fax: +44 (0) 191 208 4301
- Address: Wolfson Childhood Cancer Research Centre
Newcastle University
Herschel Building- Level 6
Brewery Lane
Newcastle upon Tyne
NE1 7RU
UK
Roles and Responsibilities
Professor of Paediatric Oncology, Newcastle University
Honorary Consultant in Paediatric & Adolescent Oncology, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust
Co-director of national neuroblastoma molecular diagnostics reference centre service 2011-
Director of Children's Cancer & Leukaemia Group (CCLG) Tumour Bank, 2016-
Qualifications
BSc (Hons), Experimental Immunology & Oncology. University of Manchester, 1988
MB ChB (Hons), Bachelor of Medicine, Bachelor of Surgery, University of Manchester, 1991
Member of the Royal College of Physicians/Paediatrics and Child Health (MRCPCH), 1994
PhD, Newcastle University, 2002
Fellow of the Royal College of Paediatrics & Child Health (FRCPCH), 2005
Previous Positions
Senior Lecturer & Honorary Consultant in Paediatric & Adolescent Oncology, 2004-2011
Lecturer & Honorary Registrar in Paediatric Oncology, 2002-2004
Department of Health Clinician Scientist Fellowship, Newcastle University, 2002-2008
Specialist Registrar in Paediatrics, Newcastle and North Tyneside Hospitals,1999-2002
Research Registrar in Paediatric Oncology, Newcastle University, 1996-1999
LRF Fellow in Paediatric Oncology, Newcastle Hospitals 1995-1996
SHO and Senior Resident in Paediatrics, John Radcliffe Hospital, Oxford and Duke University Hospital, North Carolina, USA 1993-1995
SHO and PRHO in Medicine and Surgery, Manchester Hospitals, 1991-1992
Memberships
Royal College of Paediatrics & Child Health
United Kingdom Children's Cancer and leukaemia Group (CCLG)
British Association for Cancer Research
American Association for Cancer Research
British Medical Association
Committees
NIHR Doctoral Research Fellowship Selection Committee, 2009-11
National Cancer Research Institute (NCRI) Children's Cancer & Leukaemia Clinical Studies Group, Neuroblastoma Subgroup 2010-
Newcastle Healthcare Charity Scientific Committee, 2012-
CCLG Biological Studies Steering Group, 2014-
National Cancer Research Institute (NCRI) Children's Cancer & Leukaemia Clinical Studies Group, 2016-
Chair of UK Children's Cancer & Leukaemia Group Neuroblastoma Special Interest Group, 2010-15
Medical Trustee of Neuroblastoma UK, 2010-
Friends of Rosie Charity Scientific Committee, 2016-
Honours and Awards
MB ChB with Honours, Distinction-Psychiatry, Honours- Paediatrics, Anatomy, Physiology, Biochemistry, Pharmacology, Public Health & Epidemiology
Kessel Psychiatry Prize, University of Manchester,1991
Liversege Memorial Prize for Elective Report,Boston Children's Hospital and Dana Farber Cancer Insitute,1991
Henri-Mousalli Case Presentation Award, Manchester 1992,
Young Investigator Award, Advances in Neuroblastoma Research, Bath, 1998,
Sylvia Lawler Prize, Royal Society of Medicine,London, 2001,
SPARKS Young Investigator Award, Royal College of Paediatrics & Child Health, York, 2003
Languages
English
Research Interests
Childhood neuroblastoma - biological, translational and clinical
Postgraduate Supervision
8 PhD students, 2 Staff PhD, 1 staff MPhil
21 MRes students. 2 MClin Res students, 2 MSci students
Funding
All PI unless otherwise stated
MRC Intercalated studentship, 1988
North of England Children's Cancer Research Fund, Clinical Fellowship, 1996-1999
NIHR Clinician Scientist Award, 2002-2008
Cancer Research UK, PhD studentship,2003-2007
Cancer Research UK, Continuation of a national neuroblastoma molecular diagnostic service, 2004-2006
Cancer Research UK, PhD studentship,2005-2009
Cancer Research UK, Drug Development Award, 2005-2007 (Co-I)
Neuroblastoma Society Project Grant, 2005-2008 (Co-I)
Department of Health, Continuation of a national neuroblastoma molecular diagnostic service, 2006-2008
Cancer Research UK, PhD studentship, 2007-2011 (Co-I)
Newcastle Healthcare Charity, 2007-2008
Newcastle Healthcare Charity, 2008-2010
Neuroblastoma Society, Neuroblastoma Reference Centre Service 2008-2011 (Co-I)
Cancer Research UK, PhD studentship, 2010-2014
Cancer Research UK, Small Grant, 2011-2012 (Co-I)
Neuroblastoma Society, 2010-2012
JGW Paterson Foundation, 2011-2012
Cancer Research UK, CCLG Tumour Bank, 2011-14 (Co-I)
NIHR, Flexibility & Sustainability Funding, 2011-12
SPARKS/DCCF, Project Grant, 2012-15
Children with Cancer, Project Grant, 2012-13
Cancer Research UK, CTAAC funding 2012-17
Newcastle Healthcare Charity, 2013-14
Families Against Neuroblastoma, 2013-14
Cancer Research UK, CCLG Tumour Bank, 2014-17
Neuroblastoma UK, Project Grant, 2014-16
Solving Kids Cancer, UK, 2015-17
Neuroblastoma UK/ Niamh's Next Step, Project Grant, 2015-17
NIHR Newcastle Biomedical Research Centre Project Grant, 2015-17
Wellcome Trust/Department of Health Healthcare Innovation Challenge Fund, 2015-19 (Co-I)
MRC Molecular Pathology Node, 2015-19 (Co-I)
Action Medical Research/ Great Ormond Street Hospital Children's Charity, 2016-20
JGW Paterson Foundation, 2016-17 (Co-I)
Little Princess Trust/CCLG, 2016-17
Little Princess Trust/CCLG, 2017-18
Cancer Research UK, CCLG Tumour Bank, 2017-21
Little Princess Trust/CCLG, 2017-21
Little Princess Trust/CCLG, 2018-21
NIHR Research for Patient Benefit, 2018-21 (Co-I)
Sir Bobby Robson Foundation, 2018-21
Little Princess Trust, 2018-21
Little Princess Trust, 2020-23
Solving Kids' Cancer, 2020-21
Little Princess Trust, 2021-24 (Co-I)
JGW Paterson Foundation, 2021-22
Patents
None
Undergraduate
Medical Students on wards and clinics
Bioscience students as part of undergraduate projects
Postgraduate
Postgraduates as part of research degrees- MRes, MClinRes, MSci, MPhil, MD, PhD
Junior doctors on wards and clinics
- Ambros IM, Tonini G-P, Potschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, Benard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, Ambros PF. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology 2020, 38(31), 3685-3697.
- Southgate HED, Chen L, Tweddle DA, Curtin NJ. ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms. Cancers 2020, 12(5), 1095.
- Merugu S, Chen L, Gavens E, Gabra H, Brougham M, Makin G, Ng A, Murphy D, Gabriel AS, Robinson ML, Wright JH, Burchill SA, Humphreys A, Bown N, Jamieson D, Tweddle DA. Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers. Clinical Cancer Research 2020, 26(1), 122-134.
- Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine 2020, 22, e2.
- Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology 2020, 10, 371.
- Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. European Journal of Cancer 2019, 111, 50-58.
- Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer 2019, 144(12), 3146-3159.
- Hawley J, Veal GJ, Errington J, McDonald LG, Tweddle DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression. Pediatric Blood and Cancer 2019, 66(9), 1-3.
- Chen L, Esfandiari A, Reaves W, Vu A, Hogarty MD, Lunec J, Tweddle DA. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours. International Journal of Oncology 2018, 52(3), 967-977.
- Carr-Wilkinson J, Prathalingam N, Pal D, Moad M, Lee N, Sundaresh A, Forgham H, James P, Herbert M, Lako M, Tweddle DA. Differentiation of human embryonic stem cells to sympathetic neurons: A model for understanding neuroblastoma pathogenesis. Stem Cells International 2018, 2018, 4391641.
- Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery 2017, 12(8), 801-811.
- Chen L, Pastorino F, Berry P, Bonner J, Wood K, Veal G, Ponzoni M, Lunec J, Newell DR, Tweddle DA. In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma. In: AACR Annual Meeting 2017. 2017, Washington, DC: American Association for Cancer Research.
- Gabriel AS, Chen L, Evans L, Nakjang S, Bown N, Williamson D, Tweddle DA. Combined Copy Number and Gene Expression Profiling in High Rick Neuroblastoma: A CCLG Pilot Biological Study. In: NCRI 2016. 2016, Liverpool, UK.
- Bowyer H, Exley C, Girling M, Tweddle D. Delays to Diagnosis of Childhood Cancer: A Qualitative Study of Specialist Health Care Professionals' Views. In: 48th Congress of the International Society of Paediatric Oncology (SIOP). 2016, Dublin: John Wiley & Sons, Inc.
- Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. British Journal of Cancer 2016, 115, 1048-1057.
- Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget 2016, 7, 87301-87311.
- Wright JH, Humphreys A, Gabriel AS, Bown N, Chen L, Jamieson D, Tweddle DA. Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines. In: 48th Annual Congress of the International Society of Paediatric Oncology (SIOP). 2016, Dublin, Ireland: Wiley Periodicals, Inc.
- Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clement N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA, De Preter K, Speleman F, Vandesompele J, CCLG. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget 2016, 7(2), 1960-1972.
- Mistry G, Page A, Ellershaw C, Malik G, Gamble A, Hall A, Jacques TS, Tweddle DA. The National Children's Cancer and Leukaemia Group Tissue Bank similar to Facilitating a Comprehensive Range of Paediatric Oncology Research. In: 48th Congress of the International Society of Paediatric Oncology (SIOP). 2016, Dublin, Ireland: John Wiley & Sons, Inc.
- Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RA, Tweddle DA, Jenkinson H, Picton S. Carboplatin therapeutic monitoring in preterm and full-term neonates. In: AACR 106th Annual Meeting 2015. 2015, Philadelphia, PA, USA: AACR.
- Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, Tweddle DA, Jenkinson H, Picton S. Carboplatin therapeutic monitoring in preterm and full-term neonates. European Journal of Cancer 2015, 51(14), 2022-2030.
- Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Benard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer 2015, 112(2), 290-295.
- Chen L, Tweddle DA. Neuroblastoma and the p53 Pathway. Pediatric and Adolescent Medicine 2015, 20, 59-80.
- Chen L, Tweddle DA. Neuroblastoma and the p53 pathway . In: Christiansen, H and Christiansen, NM, ed. Progressive Neuroblastoma: Innovation and Novel Therapeutic Strategies. Karger, 2015, pp.59-80.
- Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget 2015, 6(12), 10207-10221.
- Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Letters 2015, 363(1), 37-45.
- Shouksmith AE, Evans LE, Tweddle DA, Miller DC, Willmore E, Newell DR, Golding BT, Griffin RJ. Synthesis and Activity of Putative Small-Molecule Inhibitors of the F-Box Protein SKP2. Australian Journal of Chemistry 2015, 68(4), 660-679.
- Muirhead CR, Tweddle DA, Basta NO, McNally RJQ. Temporal clustering of neuroblastic tumours in children and young adults from Northern England. Environmental Health 2015, 14(1), 72.
- Veal G, Errington J, Hayden J, Hobin D, Murphy D, Dommett R, Tweddle D, Jenkinson H, Picton S. Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience. In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
- Herd F, Wheeler K, Morgenstern DA, Tweddle DA. Adherence to UK Children's Cancer and Leukaemia Group Guidelines for the Management of Low and Intermediate Risk Neuroblastoma, 2011-2013. In: 46th Congress of The International Society of Paediatric Oncology (SIOP) 2014. 2014, Toronto,Canada: Wiley-Blackwell.
- Basta N, Halliday G, Makin G, Feltbower RG, Birch JM, Bown N, Elliott M, Ingham D, Moreno L, Barome G, Pearson A, James PW, Tweddle DA, McNally RJ. Characteristics of UK patients with relapsed, intermediate risk unresectable, non-MYCN amplified neuroblastoma: a pilot study. In: Advances in Neuroblastoma Research. 2014, Cologne, Germany.
- Bell E, Ponthan F, Whitworth C, Tweddle DA, Lunec J, Redfern CPF. COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib. Clinical & Experimental Metastasis 2014, 31(6), 651-659.
- Shouksmith AE, Evans LE, Griffin RJ, Golding BT, Newell H, Miller DC, Noble MEM, Endicott JA, Tweddle D. Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex. In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
- Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson ADJ, Van Maerken T. MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets 2014, 15(1), 114-123.
- Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. British Journal of Cancer 2014, 111, 716-725.
- Muirhead CR, Tweddle DA, McNally R. Temporal Clustering of Neuroblastoma in Children and Young People from Northern England. In: 46th Congress of The International Society of Paediatric Oncology (SIOP) 2014. 2014, Toronto, Canada: Wiley-Blackwell.
- Sung PJ, Boulos N, Tilby MJ, Andrews WD, Newbold RF, Tweddle DA, Lunec J. Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation. Cancer Letters 2013, 328(1), 168-175.
- Chen L, Tweddle DA. p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Frontiers in Oncology 2012, 2, 173.
- Basta N, Halliday G, Makin G, Feltbower R, Birch J, Bown N, Elliott M, Ingham D, Moreno L, Barone G, Pearson A, James PW, Tweddle DA, McNally RJQ. Factors associated with recurrence and length of survival following relapse in patients with neuroblastoma: a pilot study. In: 44th Congress of the International Society of Paediatric Oncology (SIOP). 2012, London, UK: John Wiley & Sons, Inc.
- Gamble LD, Kees UR, Tweddle DA, Lunec J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012, 31(6), 752-763.
- Fisher JPH, Tweddle DA. Neonatal neuroblastoma. Seminars in Fetal & Neonatal Medicine 2012, 17(4), 207-215.
- Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, Cialfi S, Vergalli J, Fragliasso V, Guerzoni C, Manzotti G, Soliera AR, Menin C, Bertorelle R, McDowell HP, Inserra A, Belli ML, Varesio L, Tweddle D, Tonini GP, Altavista P, Dominici C, Raschellà G, Calabretta B. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Neoplasia 2012, 14(7), 634-643.
- Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF. A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research 2011, 17(4), 792-804.
- Carr-Wilkinson J, Griffiths R, Elston R, Goranov B, Redfern CPF, Gamble LD, Lunec J, Tweddle DA. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle 2011, 10(21), 3778-3787.
- Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. Pediatric Hematology & Oncology 2011, 28(2), 106-114.
- Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Benard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Canete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). British Journal of Cancer 2011, 105(12), 1940-1948.
- Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010, 103(10), 1588-1596.
- Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NV, Boos J, Kohler G, Leuschner I, Pearson ADJ, Lunec J, Tweddle DA. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clinical Cancer Research 2010, 16(4), 1108-1118.
- Bell E, Chen LD, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Letters 2010, 293(2), 144-157.
- Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Research 2010, 70(4), 1377-1388.
- Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research 2009, 15(4), 1241-1249.
- Bell, E., Lunec, J., Tweddle, D. Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 2007, 6(10), 1249-1256.
- Chen L, Malcolm AJ, Wood K, Cole M, Variend S, Cullinane C, Pearson ADJ, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6(21), 2685-2696.
- Carr J, Bell E, Pearson ADJ, Kees U, Beris H, Lunec J, Tweddle DA. Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse. Cancer Research 2006, 66(4), 2138-2145.
- Tweddle, D.A., Pearson, A.D.J., Haber, M., Norris, M., Xue, C., Flemming, C., Lunec, J. The p53 pathway and its inactivation in neuroblastoma. Cancer Letters 2003, 197(1-2), 93-98.
- Tweddle, D. A., Malcolm, A. J., Bown, N. P., Pearson, A. D. J., Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Research 2001, 61(1), 8-13.
- Tweddle, D. A., Malcolm, A. J., Cole, M., Pearson, A. D. J., Lunec, J. p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells. American Journal of Pathology 2001, 158(6), 2067-2077.